Mission line

A new Model to model Humans.

Only 30% of drugs show effect in Phase II. Yet 60% of approved drugs later find new uses. Same molecule. Different patients. Different disease. Different answer. The difference? Not the drug, but the patient, the disease, and the context. We model human response before the trial, helping teams find the indications, patients, and endpoints where the biology is most likely to work.

Contact

Capability

Find where a drug is most likely to work before Phase II makes the call. We model human response across patients, diseases, and endpoints to reveal the clinical paths most likely to succeed.

Methodology

In silico clinical trials run across patient cohorts in hours, not years. We translate mechanism, biomarkers, and trial endpoints into predictive models that surface the indications most likely to succeed.

Validation

Predictions compared against real-world outcomes across thousands of programs. We measure accuracy continuously and recalibrate as biology, patient data, and clinical evidence evolve.

Atlas foundational Model accurately captures Human Biology.

561 K

Patients to enroll into virtual clinical trials.

6.35 B

20 K

561 K

Patients to enroll into virtual clinical trials.

6.35 B20 K

Actively used to discover novel Insights.

The Founding Team.

A cross-functional team of scientists, engineers, and clinical experts building at the edge of AI and drug development. We work closely with pharma teams to translate mechanisms, patient biology, and clinical questions into predictive in silico trials, combining deep scientific review with fast, productized execution. The model does the heavy lifting. The team makes sure the biology is right.

Backed by the Best:

and Founders of the World's leading AI Labs.

A new Model to model Humans.

The Founding Team.

Clinical Trials cost up to $1B. 90% of clinical Programs fail.